Healthcare Providers and Services
Company Overview of ARUP Laboratories, Inc.
ARUP Laboratories, Inc. operates as a clinical and anatomic pathology reference laboratory in the United States. It offers testing services in the areas of anatomic pathology, pain management, genetics, pediatrics, infectious disease, oncology, and other specialties. The company also provides analytics, monitoring, consulting, collaboration, and decision support services; and clinical trials services for contract research organizations and central laboratories, global and startup organizations, pharmaceutical companies, multinational companies, and key IVD and biotechnology companies. In addition, it offers ARUP Connect, an online resource for referral testing; point-of-care diagnostic and i...
500 Chipeta Way
Salt Lake City, UT 84108
Founded in 1984
Key Executives for ARUP Laboratories, Inc.
Chief Executive Officer and President
Chief of Clinical Pathology, Senior Vice President of Research & Development, Section Chief of Hematopathology, Medical Director and Executive Director of ARUP Institute for Clinical & Experimental Pathology
Section Chief of Biochemical Genetics and Medical Director of Biochemical Genetics & Newborn Screening
Section Chief of Molecular Genetics & Genomics
Compensation as of Fiscal Year 2016.
ARUP Laboratories, Inc. Key Developments
ARUP Laboratories Appoints Edgar Braendle as CEO Effective August 16, 2016
Jul 7 16
ARUP Laboratories announced that Edgar Braendle, MD, PhD, has been named CEO, effective August 16, 2016. Throughout the search process, Dean Li, MD, PhD, has served as interim CEO, ensuring a smooth transition in leadership. Prior to joining ARUP, Braendle held multiple leadership roles at Novartis Pharmaceutical Corporation and Schering AG. Most recently, he was senior vice president and global head of Companion Diagnostics at Novartis.
ARUP Laboratories and the Children's Hospital of Philadelphia Form Partnership to Offer High-Resolution HLA Genotyping by Next Generation Sequencing
Oct 8 14
ARUP Laboratories announced that they will be offering high-resolution HLA genotyping by next generation sequencing (NGS) under an agreement with The Children's Hospital of Philadelphia (CHOP). HLA genotyping is used for identifying the best recipient/donor match combination prior to hematopoietic stem cell transplantation (HSCT). HLA genes are the most polymorphic gene family found in the entire human genome, with more than 10,000 different HLA alleles reported so far. Currently, the standard of care for HLA genotyping to select a donor for HSCT is to use a low/intermediate resolution SSO/SSP test first and then reflex the candidates to confirmatory Sanger Sequence Based Typing (SBT) to obtain higher resolution allele information to finalize the matched donor. Sanger SBT produces incomplete and ambiguous results by analyzing only sections of the HLA genes and failing to distinguish among different alleles due to difficulty with resolving cis/trans chromosomal positions of those alleles. NGS is able to overcome the limitations of Sanger SBT by performing large number of long clonal sequencing reactions, allowing reporting of complete and unambiguous HLA genotyping results.
Similar Private Companies By Industry
Recent Private Companies Transactions